HLS Therapeutics (TSE:HLS) Hits New 52-Week Low – Time to Sell?

HLS Therapeutics Inc. (TSE:HLS)’s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as C$4.00 and last traded at C$4.00, with a volume of 12846 shares changing hands. The stock had previously closed at C$4.14.

HLS Therapeutics Stock Performance

The company has a debt-to-equity ratio of 75.00, a current ratio of 1.00 and a quick ratio of 1.01. The firm has a market capitalization of C$132.61 million, a PE ratio of -13.25 and a beta of -0.02. The company’s fifty day simple moving average is C$4.53 and its 200 day simple moving average is C$4.56.

HLS Therapeutics (TSE:HLS) last posted its earnings results on Friday, May 15th. The company reported C($0.10) earnings per share for the quarter. HLS Therapeutics had a negative return on equity of 16.54% and a negative net margin of 18.42%.The business had revenue of C$17.88 million during the quarter. As a group, equities research analysts expect that HLS Therapeutics Inc. will post -0.12 EPS for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.